Biogen’s partner, Japan-based Eisai, leads the clinical development and regulatory submissions for Leqembi. Though both companies co-commercialize and co-promote the drug, Eisai has the final ...

Nine months after the U.S. launch of Eisai Limited (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Leqembi, the first drug shown to slow Alzheimer’s progression, adoption faces hurdles due to ...

Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.

In a widely-anticipated study, Eisai and Biogen on Tuesday said their Alzheimer's drug slowed cognitive decline among people with early signs of the disease. The study, led by Eisai, which has ...

Non-APOE4 carriers do not benefit from treatment with lecanemab, which reduces the rate of progression of APOE4 carriers. Read more here.

Biogen and its partner Eisai said Tuesday night that their experimental Alzheimer’s disease therapy successfully slowed the memory-robbing condition in a large clinical trial. The results set ...

Biogen and Eisai have begun a new phase 3 study testing an Alzheimer’s antibody drug aimed at patients without symptoms but with elevated levels of amyloid in their brains, the protein aggregate ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer's disease with a claim that their new drug lecanemab showed a "highly statistically ...

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally. Both Eisai and Biogen co-commercialize and co-promote the product, and Eisai has final decision-making ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi (lecanemab) for early Alzheimer’s disease (AD).